Intest (INTT) Q2 2025: Auto EV Orders Jump 40% as Diversification Offsets Semi Weakness
Intest’s Q2 2025 results highlight effective diversification, with Auto EV, Life Sciences, and Defense Arrow offsetting persistent semiconductor softness. Operational discipline and new product traction are supporting margins, while the Malaysia facility ramps as a strategic hedge. The pipeline is at an all-time high, but management remains cautious on timing for a broader capex recovery.
Summary
- Auto EV and Life Sciences Drive Order Strength: Orders surged in Auto EV and Life Sciences, validating diversification strategy.
- Cost Actions and New Product Mix Support Margins: Gross margin improvement and expense control partially shield against end-market volatility.
- Malaysia Facility Ramps as Tariff Hedge: Regional expansion aims to boost competitiveness and mitigate supply chain risks.
Performance Analysis
Intest delivered $28.1 million in Q2 revenue, with gross margin improving sequentially to 42.6%. The company’s order book reflected notable strength in Auto EV (up 40% sequentially), Life Sciences (more than doubled), and Safety Security (up 74%), while CEMI (semiconductor) orders fell 24% as that market remains sluggish. Backlog held steady at $37.9 million, providing visibility but reflecting the ongoing softness in certain legacy segments.
Gross profit rose sequentially on higher volumes and cost reductions, with a 110 basis point margin improvement over Q1. Year-over-year, revenue declined due to a $4.9 million drop in Auto EV sales, partially offset by gains in Industrial and Safety Security. Operating expenses fell by $1 million QoQ, reflecting headcount reductions and austerity measures, while adjusted EBITDA reached $1.3 million. Cash flow supported further debt reduction, with net leverage at 1.4x and liquidity described as ample.
- Auto EV and Life Sciences Orders Surge: Sequential order growth in these segments offset semiconductor softness, with Auto EV reaching $7.1 million.
- Margin Levers Realized: Cost discipline and favorable mix drove margin gains despite volume headwinds.
- Backlog Stability: Flat sequential backlog signals steady near-term demand, but YoY decline reflects prior large acquisition impact.
New products contributed $6 million in sales (over 20% of total), supporting the company’s vitality metric and positioning Intest for future growth as markets recover.
Executive Commentary
"While the ongoing global economic and tariff uncertainties continue to drive customer hesitancy as it relates to moving forward with larger capital projects, we were able to deliver incremental improvement in the quarter...our funnel of opportunities has increased to a new all-time high as customers recognize our innovative solutions are integral to their long-term capital plans."
Nick Grant, President & Chief Executive Officer
"Our operating expenses of 12.9 million also reflect recent cost reduction efforts with a sequential decrease of 1 million...we further reduced headcount during Q2 and employed austerity measures versus our budgeted 2025 spend."
Duncan Gilmore, Chief Financial Officer & Treasurer
Strategic Positioning
1. Diversification Beyond Semiconductors
Intest’s pivot to Auto EV, Life Sciences, and Defense Arrow is yielding tangible results, with order growth in these segments helping to offset the cyclical downturn in CEMI. The company’s alfamation business, acquired in 2024, is now delivering its highest order levels since joining Intest, including a key win in Life Sciences that broadens its exposure.
2. Regional Manufacturing Expansion
The Malaysia facility, regional manufacturing hub, is on track to begin production in the second half of 2025, with a five-year ramp plan targeting $10–15 million in annual output. This initiative enhances supply chain flexibility, reduces tariff exposure, and supports localized customer needs in Asia, while also freeing up capacity at existing facilities for North America and Europe.
3. Product Innovation and Vitality
New products accounted for over 20% of Q2 sales, advancing the company toward its Vision 2030 goal of 25% vitality. These innovations are opening doors to new accounts and underpinning the growing opportunity funnel, which management describes as the largest in company history.
4. Operational Discipline and Cost Control
Expense reductions, headcount actions, and restructuring have helped protect margins and cash flow in a challenging demand environment. The consolidation of the Videology Netherlands facility and a leaner executive structure are expected to yield further savings into 2026.
5. Capital Structure and Liquidity Management
Debt reduction remains a priority, with $4.9 million paid down year-to-date and a net cash position providing flexibility. A covenant waiver agreement with the company’s US lender ensures continued liquidity through early 2026, even as cash is pledged against US debt.
Key Considerations
Intest’s Q2 demonstrates a measured approach to uncertainty, balancing cost controls with strategic investments and market expansion. The company’s diversified order growth and new product traction provide a buffer against end-market volatility, but recovery in semiconductors remains a key swing factor for upside.
Key Considerations:
- Auto EV and Life Sciences Momentum: Continued order wins and pipeline strength signal sustainable diversification impact.
- Semiconductor Market Cyclicality: CEMI remains weak, with front-end recovery now expected in 2026.
- Malaysia Facility Execution: Timely ramp and customer adoption will be critical to achieving targeted cost and growth benefits.
- Cost Controls vs. Scalability: Temporary austerity measures may need to be reversed as demand returns, requiring careful balance between expense discipline and readiness for growth.
Risks
End-market uncertainty in semiconductors and global capital spending continues to cloud visibility, with management explicitly limiting guidance to a single quarter. Tariff and trade volatility, as well as execution risk in ramping the Malaysia facility, could pressure margins or delay growth. The company’s cost actions, while prudent, may challenge scalability if demand rebounds rapidly.
Forward Outlook
For Q3 2025, Intest guided to:
- Revenue of $28–30 million
- Gross margins similar to Q2 (around 42%)
- Operating expenses of $12.6–13.1 million (excluding restructuring)
For full-year 2025, management did not provide formal guidance, citing limited visibility but reiterated confidence in sequential improvement and long-term fundamentals.
Management highlighted several factors that will shape the outlook:
- Order pipeline at record levels, but timing of conversion remains uncertain
- Semiconductor front-end recovery unlikely before 2026
Takeaways
Intest’s Q2 underscores the value of diversification, cost discipline, and regional expansion in navigating end-market uncertainty.
- Order Growth in Diversified Segments: Auto EV and Life Sciences are offsetting semiconductor headwinds, validating recent strategic investments.
- Margin and Cash Flow Resilience: Cost actions and favorable mix support profitability, even as revenue remains below prior-year levels.
- Malaysia Ramp and Semi Recovery as Key Catalysts: Successful execution in regional manufacturing and a semiconductor rebound will determine the next phase of growth.
Conclusion
Intest’s Q2 2025 results reflect a company effectively managing through industry volatility by leveraging diversification, new product vitality, and disciplined operations. While near-term demand visibility is limited, the long-term opportunity funnel and regional expansion position Intest for upside as capital spending cycles recover.
Industry Read-Through
Intest’s experience this quarter echoes broader industry themes: semiconductor capital equipment remains in a cyclical trough, while demand in Auto EV and Life Sciences is proving more resilient. The company’s regional manufacturing push in Malaysia is emblematic of a broader trend among industrial and test equipment firms seeking to insulate supply chains from tariff and geopolitical risk. Investors should watch for similar diversification and regionalization strategies across the sector, as well as the timing and magnitude of semiconductor recovery signals heading into 2026.